These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 9512972)

  • 21. [Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
    Matzkies F; Berg G; Minzlaff R
    Fortschr Med; 1977 Jul; 95(27):1748-50. PubMed ID: 332605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F; Neuwirth R; Berg G
    Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Uric-acid reduction with high allopurinol dosages (author's transl)].
    Mertz DP; Loewer H
    Dtsch Med Wochenschr; 1979 Mar; 104(9):324-5. PubMed ID: 761542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Matzkies F
    Fortschr Med; 1983 May; 101(20):953-9. PubMed ID: 6873850
    [No Abstract]   [Full Text] [Related]  

  • 25. Benzbromarone therapy in management of refractory gout.
    Kumar S; Ng J; Gow P
    N Z Med J; 2005 Jun; 118(1217):U1528. PubMed ID: 15980902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperuricemia and gout.
    Sloan RW
    J Fam Pract; 1982 May; 14(5):923-6, 930-1, 934. PubMed ID: 7042900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anorexia nervosa with refeeding syndrome: prevention and treatment of RS].
    Kasai M; Okajima Y; Takano E; Kato S
    Seishin Shinkeigaku Zasshi; 2009; 111(4):388-97. PubMed ID: 19594099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia.
    Fraser RC; Davis RH; Walker FS
    J R Coll Gen Pract; 1987 Sep; 37(302):409-11. PubMed ID: 3330140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection.
    Reinders MK; Nijdam LC; van Roon EN; Movig KL; Jansen TL; van de Laar MA; Brouwers JR
    J Pharm Biomed Anal; 2007 Oct; 45(2):312-7. PubMed ID: 17890037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
    Mertz DP
    Fortschr Med; 1983 May; 101(18):851-3. PubMed ID: 6862346
    [No Abstract]   [Full Text] [Related]  

  • 32. [On the dose-effect relation of allopurinol (author's transl)].
    Mertz DP
    Arzneimittelforschung; 1977; 27(6):1209-11. PubMed ID: 578444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial hyperuricemia and renal insufficiency.
    Foreman JW; Yudkoff M
    Child Nephrol Urol; 1990; 10(2):115-8. PubMed ID: 2253250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
    Perez-Ruiz F; Calabozo M; Erauskin GG; Ruibal A; Herrero-Beites AM
    Arthritis Rheum; 2002 Dec; 47(6):610-3. PubMed ID: 12522834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hyperuricemia and gout: therapeutic indications].
    Pawlotsky Y
    Rev Prat; 1994 Jan; 44(2):206-9. PubMed ID: 8178077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of allopurinol on the indicators of immunity in podagra and experimental hyperuricemia].
    Siniachenko OV; Nikolenko IuI; Diadyk AI; Bortnik VA; Okushko RV
    Revmatologiia (Mosk); 1991; (1):12-5. PubMed ID: 2068454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly.
    Franchi C; Salerno F; Conca A; Djade CD; Tettamanti M; Pasina L; Corrao S; Marengoni A; Marcucci M; Mannucci PM; Nobili A;
    Eur J Intern Med; 2014 Nov; 25(9):847-52. PubMed ID: 25439099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.